CH637297A5
(fr)
*
|
1978-12-05 |
1983-07-29 |
Nestle Sa |
Microbille comprenant un microorganisme et son procede de fabrication.
|
US4421736A
(en)
*
|
1982-05-20 |
1983-12-20 |
Merrel Dow Pharmaceuticals Inc. |
Sustained release diethylpropion compositions
|
US4507276A
(en)
*
|
1982-08-20 |
1985-03-26 |
Bristol-Myers Company |
Analgesic capsule
|
FR2548021B1
(fr)
*
|
1983-06-29 |
1986-02-28 |
Dick P R |
Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
|
NL8500724A
(nl)
*
|
1985-03-13 |
1986-10-01 |
Univ Groningen |
Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
|
US4755387A
(en)
*
|
1985-03-21 |
1988-07-05 |
The Procter & Gamble Company |
Therapeutic particles
|
US4863741A
(en)
*
|
1985-03-25 |
1989-09-05 |
Abbott Laboratories |
Tablet composition for drug combinations
|
US4874614A
(en)
*
|
1985-03-25 |
1989-10-17 |
Abbott Laboratories |
Pharmaceutical tableting method
|
CA1279574C
(en)
*
|
1985-04-17 |
1991-01-29 |
Jeffrey L. Finnan |
Process for lubricating water-soluble vitamin powders
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
SE8701479L
(sv)
*
|
1987-04-09 |
1988-10-10 |
Carbomatrix Ab |
Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
|
FI77573C
(fi)
*
|
1987-05-08 |
1989-04-10 |
Orion Yhtymae Oy |
Ny konsistens.
|
JP2668880B2
(ja)
*
|
1987-06-23 |
1997-10-27 |
日本油脂株式会社 |
被覆アミノ酸類の製造方法
|
DE3721721C1
(de)
*
|
1987-07-01 |
1988-06-09 |
Hoechst Ag |
Verfahren zur Umhuellung von Granulaten
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US5328697A
(en)
*
|
1992-02-10 |
1994-07-12 |
Mallinckrodt Veterinary, Inc. |
Compositions and processes for the sustained release of drugs
|
DE60007552T2
(de)
|
1999-12-10 |
2004-09-23 |
Pfizer Products Inc., Groton |
PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
EP1268455A2
(en)
*
|
2000-03-31 |
2003-01-02 |
Pfizer Products Inc. |
Piperazine derivatives
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
EP1326867A2
(en)
*
|
2000-10-19 |
2003-07-16 |
Pfizer Products Inc. |
Bridged piperazine derivatives
|
IL158461A0
(en)
|
2001-06-20 |
2004-05-12 |
Pfizer Prod Inc |
Novel sulfonic acid derivatives
|
IL160974A0
(en)
*
|
2001-10-22 |
2004-08-31 |
Pfizer Prod Inc |
Piperazine derivatives with ccr1 receptor antagonist activity
|
WO2003095439A1
(en)
*
|
2002-05-14 |
2003-11-20 |
Pfizer Products Inc. |
Methods for manufacture of dihydro-furan-2-one derivatives
|
CA2484860A1
(en)
*
|
2002-05-14 |
2003-11-20 |
Pfizer Products Inc. |
Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
|
PA8575901A1
(es)
*
|
2002-07-18 |
2004-07-20 |
Pfizer Prod Inc |
Derivados de piperidina novedosos
|
MXPA05001781A
(es)
*
|
2002-08-12 |
2005-04-25 |
Pfizer Prod Inc |
Formas cristalinas de [4-carbamoil -1-(3- fluorobencil)-2, 7-dihidroxi- 7-metil- octil]-amida del acido quinoxalina-2- carboxilico.
|
EP2165708A3
(en)
|
2002-09-18 |
2010-07-28 |
Pfizer Products Inc. |
New pyrazole derivatives as transforming growth factor (TGF) inhibitors
|
US20040097554A1
(en)
*
|
2002-10-30 |
2004-05-20 |
Pfizer Inc |
Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
|
US20040087571A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Pfizer Inc |
Methods of using CCR1 antagonists as immunomodulatory agents
|
US20040116441A1
(en)
*
|
2002-10-30 |
2004-06-17 |
Pfizer Inc |
Methods of using sulfonic acid derivatives
|
MXPA05005403A
(es)
*
|
2002-11-21 |
2005-08-03 |
Pfizer Prod Inc |
Derivados de 3-amino-piperadina y metodos de fabricacion.
|
JP2006509000A
(ja)
*
|
2002-11-26 |
2006-03-16 |
ファイザー・プロダクツ・インク |
移植片拒絶反応の処置の方法
|
JP2006509815A
(ja)
*
|
2002-12-13 |
2006-03-23 |
ファイザー・プロダクツ・インク |
新規なリン含有誘導体
|
PA8591801A1
(es)
|
2002-12-31 |
2004-07-26 |
Pfizer Prod Inc |
Inhibidores benzamidicos del receptor p2x7.
|
WO2004072072A1
(en)
*
|
2003-02-14 |
2004-08-26 |
Pfizer Products Inc. |
Triazolo-pyridines as anti-inflammatory compounds
|
PA8595001A1
(es)
*
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
CA2517720A1
(en)
|
2003-03-11 |
2004-09-23 |
Pfizer Products Inc. |
Pyrazine compounds as transforming growth factor (tgf) inhibitors
|
US20050119275A1
(en)
*
|
2003-06-24 |
2005-06-02 |
Pfizer Inc. |
Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
|
WO2005051393A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
TW201038578A
(en)
|
2009-01-30 |
2010-11-01 |
Univ Rutgers |
Methods to treat cancer
|
US8461102B2
(en)
*
|
2010-03-02 |
2013-06-11 |
George E. Royster, JR. |
Methods and compositions for treating and preventing symptoms of hormonal variations
|
WO2012129084A2
(en)
|
2011-03-18 |
2012-09-27 |
Genzyme Corporation |
Glucosylceramide synthase inhibitors
|
EP2709991B1
(en)
|
2011-05-16 |
2020-09-02 |
Genzyme Corporation |
Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
|
WO2013037065A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
JP6378308B2
(ja)
|
2013-03-13 |
2018-08-22 |
ボストン バイオメディカル, インコーポレイテッド |
がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
|
AU2014339897A1
(en)
|
2013-10-24 |
2016-04-21 |
Abbvie Inc. |
JAK1 selective inhibitor and uses thereof
|
BR112017002001B1
(pt)
|
2014-07-31 |
2022-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compostos e composição farmacêutica
|
MA41202A
(fr)
|
2014-12-18 |
2017-10-24 |
Genzyme Corp |
Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
|
WO2016139227A1
(en)
|
2015-03-03 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fgfr3 antagonists
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
EP3481806B1
(en)
|
2016-07-08 |
2023-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
4-anilino-quinoline compounds as anti-cancer agents
|
JP7268053B2
(ja)
|
2018-01-05 |
2023-05-02 |
アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・(インセルム) |
置換ハロキノリン誘導体、その調製方法及び適用
|
WO2020072797A1
(en)
|
2018-10-03 |
2020-04-09 |
Tesaro, Inc. |
Niraparib salts
|
WO2020072796A1
(en)
|
2018-10-03 |
2020-04-09 |
Tesaro, Inc. |
Crystalline forms of niraparib freebase
|
WO2020163245A1
(en)
|
2019-02-04 |
2020-08-13 |
Genzyme Corporation |
Methods for treating symptoms and disorders associated with lysosomal storage diseases
|
WO2020163337A1
(en)
|
2019-02-04 |
2020-08-13 |
Genzyme Corporation |
Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
|
US20210251982A1
(en)
|
2020-02-03 |
2021-08-19 |
Genzyme Corporation |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|
BR112023000798A2
(pt)
|
2020-07-24 |
2023-02-07 |
Genzyme Corp |
Composições farmacêuticas compreendendo venglustat
|
WO2022072397A1
(en)
|
2020-09-30 |
2022-04-07 |
Bioverativ Therapeutics Inc. |
Ampk activators and methods of use thereof
|
TW202241888A
(zh)
|
2020-12-23 |
2022-11-01 |
美商健臻公司 |
氘化群落刺激因子-1受體(csf-1r)抑制劑
|
WO2023196640A1
(en)
|
2022-04-08 |
2023-10-12 |
Bioverativ Therapeutics Inc. |
Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
|
WO2024116127A1
(en)
|
2022-12-01 |
2024-06-06 |
Genzyme Corporation |
Venglustat in combination with a strong or moderate inhibitor of cyp3a4
|